STOCK TITAN

Vanguard holds 243.5M Johnson & Johnson (NYSE: JNJ) shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group reports beneficial ownership of 243,455,135 shares of Johnson & Johnson common stock, representing 10.1% of the class as of 01/30/2026.

Vanguard has no sole voting or dispositive power. It has shared voting power over 24,005,159 shares and shared dispositive power over all 243,455,135 shares. The shares are held for clients, who are entitled to dividends and sale proceeds, with no single client holding more than 5% of the class.

Vanguard states the position is held in the ordinary course of business and not to change or influence control of Johnson & Johnson. Following an internal realignment on 01/12/2026, certain Vanguard subsidiaries or business divisions may report beneficial ownership separately while pursuing the same investment strategies as before.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting. In accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:02/05/2026

FAQ

How much Johnson & Johnson (JNJ) stock does The Vanguard Group report owning?

The Vanguard Group reports beneficial ownership of 243,455,135 Johnson & Johnson common shares, representing 10.1% of the outstanding class as of January 30, 2026. These shares are largely held for Vanguard’s clients, including registered investment companies and other managed accounts.

What voting and dispositive power does Vanguard have over its JNJ shares?

Vanguard reports no sole voting or dispositive power over Johnson & Johnson shares. It has shared voting power over 24,005,159 shares and shared dispositive power over 243,455,135 shares, reflecting how its investment management structure allocates decision-making across clients and affiliated entities.

Is Vanguard’s Johnson & Johnson stake a passive investment?

Yes. Vanguard certifies the JNJ securities were acquired and are held in the ordinary course of business, not to change or influence control of Johnson & Johnson. The position is reported on a Schedule 13G/A, which is the form typically used for passive institutional investors.

How does Vanguard’s internal realignment affect its JNJ ownership reporting?

Following an internal realignment effective January 12, 2026, Vanguard no longer performs portfolio management or proxy voting directly. Certain subsidiaries or business divisions that share the same strategies may report Johnson & Johnson ownership separately on a disaggregated basis, consistent with SEC guidance.

Who ultimately benefits from Vanguard’s Johnson & Johnson holdings?

Vanguard states its clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds from the Johnson & Johnson shares reported. No single other person’s interest in these securities exceeds 5% of the outstanding class.
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Latest News

JNJ Latest SEC Filings

JNJ Stock Data

564.91B
2.41B
0.06%
74.37%
0.78%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW BRUNSWICK